SemBioSys Genetics’ Apo AI(Milano) program progress update (News-Medical-Net)

December 25th, 2009 by admin

SemBioSys Genetics Inc. provided an update today on its progress on plant-produced Apo AI(Milano) in light of the Apo AI(Milano) license agreement between Pfizer Inc. and The Medicines Company, of Parsippany, New Jersey.

This entry was posted on Friday, December 25th, 2009 at 12:10 am and is filed under Genetics, Human Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.